CD274 and non-small cell lung carcinoma: From this point of view, NSCLC with negative PD-L1, low-TMB and wild-type KMT2C/BCOR/KDM5C is unlikely to be responsive to ICB therapy, and treatments other than ICB may be considered for those NSCLC patients.